GlassScriptPhysician profile
Eduardo Gallegos
NPI 1548218522
$87,415.85
in general payments reported to CMS, 2019-2025
65 companies · $3,780 in 2025
The $3,780 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $18K · 2021: $23K · 2022: $12K · 2023: $6,860 · 2024: $7,449 · 2025: $3,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,741 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,313 · Education: $34.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,741.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,312.50 |
| Education | $34.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,434.90 | 2021-2025 | |
| Acorda Therapeutics, INC | $23,702.80 | 2019-2022 | |
| Mdd US Operations, LLC | $9,817.39 | 2019-2025 | Gocovri, Apokyn |
| Allergan, INC. | $7,831.80 | 2019-2021 | |
| Sk Life Science, INC. | $1,735.38 | 2020-2025 | Xcopri |
| Biogen, INC. | $1,629.46 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,622.60 | 2019-2025 | Zilbrysq, Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,478.76 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,370.68 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,296.21 | 2019-2025 | Uplizna, Aimovig |
| Emd Serono, INC. | $888.49 | 2019-2025 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $853.95 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $718.63 | 2019-2023 | Oxtellar Xr, Trokendi Xr |
| Argenx US, INC. | $597.09 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $593.20 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Gallegos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.